Powder: -20°C for 3 years | In solvent: -80°C for 1 year
FRAX-1036 is a effective and selective PAK1 inhibitor.
説明 | FRAX-1036 is a effective and selective PAK1 inhibitor. |
ターゲット&IC50 | PAK2:72.4 nM(Ki), PAK1:23.3 nM(Ki), PAK4:2.4 μM(Ki) |
In vitro | MDA-MB-175 cells,which are PAK1-amplified (MEK1-S298 and CRAF-S338) ,was observed Potent cellular inhibition at 2.5 to 5 μM concentrations of FRAX1036. PAK1-amplified breast cancer cells are treated with FRAX1036 leading to apoptosis. OVCAR-3 cells are treated with FRAX-1036 resulting in upregulation of p53 and p21, while down-regulating cyclin B1. |
In vivo | KT21 are treated with Frax1036 showing slower tumor growth, while Frax1036 is unlikely to have significant blood-brain barrier permeability in mice. |
細胞研究 | MDA-MB175 cells are treated with increasing concentrations (0, 0.5, 1, 2.5, 5 μM) of FRAX1036 for 24 hours. |
動物実験 | Pak2-deficient mice were treated by oral gavage of 30 mg/kg Frax1036. |
分子量 | 518.05 |
分子式 | C28H32ClN7O |
CAS No. | 1432908-05-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: insoluble
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
FRAX1036 1432908-05-8 Cytoskeletal Signaling PAK Inhibitor p21 activated kinases inhibit FRAX-1036 FRAX 1036 inhibitor